Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pittsburgh experience with botulinum toxin A injection].

F de Miguel1, M B Chancellor

  • 1Departamento de Urología, Universidad de Pittsburgh, PA 15213, USA. demifx@upmc.edu

Actas Urologicas Espanolas
|June 6, 2006
PubMed
Summary

Botulinum toxin A injections effectively treat various lower urinary tract dysfunctions in 110 patients, reducing incontinence and voiding symptoms for at least six months with no long-term complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyaluronic acid effect on adipose-derived stem cells. Biological in vitro evaluation.

Revista espanola de cirugia ortopedica y traumatologia·2014
Same author

Pelvic organ cross-sensitization to enhance bladder and urethral pain behaviors in rats with experimental colitis.

Neuroscience·2014
Same author

Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells.

International urology and nephrology·2014
Same author

Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions.

Neuromodulation : journal of the International Neuromodulation Society·2011
Same author

Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Gene therapy·2009
Same author

Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats.

Gene therapy·2009

Area of Science:

  • Urology
  • Neurology
  • Pharmacology

Context:

  • Lower urinary tract dysfunction affects millions globally.
  • Existing treatments for conditions like overactive bladder and neurogenic detrusor overactivity have limitations.
  • Botulinum toxin A (BONT-A) offers a novel therapeutic approach targeting smooth and skeletal muscle dysfunction.

Purpose:

  • To evaluate the six-year experience of using botulinum toxin A (BONT-A) in the bladder and urethra for treating diverse lower urinary tract dysfunctions.
  • To assess the efficacy, safety, and duration of BONT-A treatment in a cohort of 110 patients.
  • To analyze patient-reported outcomes and urodynamic changes following BONT-A injections.

Summary:

  • 110 patients (19-82 years) received BONT-A injections into the bladder (n=42) or urethra (n=68) for conditions including neurogenic detrusor overactivity, overactive bladder, benign prostatic hyperplasia, and interstitial cystitis.

Related Experiment Videos

  • 67.3% of patients reported a significant decrease or complete resolution of incontinence.
  • Improvements in daytime and nighttime voiding symptoms and quality of life scores were observed within 7 days, lasting over 6 months.

    • Impact:

    • BONT-A injections demonstrate a favorable safety profile with no reported long-term complications.
    • The treatment is effective in both men and women, offering a promising alternative for refractory lower urinary tract symptoms.
    • BONT-A provides a safe and effective option for managing detrusor overactivity and other voiding dysfunctions, potentially improving patient quality of life.